Share chart PFIZER
Extended chart
Simple chart
About PFIZER
Pfizer Inc. обнаруживает, разрабатывает, производит, продает, распространяет и продает биофармацевтические продукты по всему миру. Он предлагает лекарства и вакцины в различных терапевтических областях, включая сердечно-сосудистый метаболизм и обезболивание, под торговыми марками Eliquis, Chantix / Champix и Premarin; биопрепараты, малые молекулы, иммунотерапевтические препараты и биоаналоги под брендами Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena и Braftovi; стерильные инъекционные и противоинфекционные препараты торговых марок Сульперазон, Медрол, Зитромакс, Вифенд и Панзига. more detailsMain settings
IPO date
2012-08-13
ISIN
US7170811035
Industry
Pharmaceuticals
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
7.06
Дивиденд ао
0.43
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 2.37 | 6 |
| P/BV | 1.7 | 8 |
| P/E | 18.75 | 7 |
Efficiency
| Title | Value | Grade |
| ROA | 3.65 | 1 |
| ROE | 9.06 | 3 |
| ROIC | 23.27 | 7 |
Dividends
| Title | Value | Grade |
| Dividend yield | 6.21 | 10 |
| DSI | 0.9286 | 9.29 |
| Average dividend growth | 3.95 | 6.59 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | 3.51 | 3 |
| Debt/Ratio | 0.2983 | 10 |
| Debt/Equity | 0.7216 | 9 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 51.82 | 7 |
| Yield Ebitda, % | 28.83 | 4 |
| Yield EPS, % | 12.72 | 2 |
Dividends
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 24.84 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Week | 23.35 $ | 23.35 $ | 24.84 $ | 6.38 % | 0 % | 0 % |
| Month | 23.04 $ | 22.83 $ | 24.84 $ | 7.81 % | 0 % | 0 % |
| Three month | 22.49 $ | 21.59 $ | 26.31 $ | 10.45 % | 0 % | 0 % |
| Half a year | 25.87 $ | 21.59 $ | 27.13 $ | -3.98 % | 0 % | 0 % |
| Year | 28.92 $ | 21.59 $ | 31.39 $ | -14.11 % | 0 % | 0 % |
| 3 years | 45.7 $ | 21.59 $ | 54.48 $ | -45.65 % | 0 % | 0 % |
| 5 years | 35.65 $ | 21.59 $ | 61.25 $ | -30.32 % | 0 % | 0 % |
| 10 years | 29.59 $ | 21.59 $ | 61.25 $ | -16.06 % | 0 % | 0 % |
| Year to date | 25.53 $ | 21.59 $ | 27.13 $ | -2.7 % | 0 % | 0 % |
Insider trading
Main owners
Contained in ETF
| ETF | Share, % | Profitability for 1 year, % | Commission, % |
| John Hancock Multifactor Healthcare ETF | 4.93 | 29.34 | 0.40 |
| Apex Healthcare ETF | 3.92 | 0 | 0.95 |
| Direxion S&P 500 High minus Low Quality ETF | 2.76 | 27.31 | 0.37 |
| Global Beta Low Beta ETF | 2.42 | 19.88 | 0.29 |
| ROC ETF | 2.21 | 0 | 0.49 |
| Franklin LibertyQ Global Dividend ETF | 2.15 | 30.37 | 0.45 |
| FlexShares Quality Dividend Dynamic Index Fund | 2.13 | 33.57 | 0.37 |
| Global Beta Smart Income ETF | 1.84067 | -8.5 | 0.45 |
| iShares Factors US Value Style ETF | 1.71 | 42.34 | 0.25 |
| Nationwide Maximum Diversification U.S. Core Equity ETF | 1.54 | 26.65 | 0.34 |
| Knowledge Leaders Developed World ETF | 1.13981 | -2.72 | 0.75 |
| Franklin LibertyQ Global Equity ETF | 1.05 | 25.84 | 0.35 |
| iShares Morningstar Large-Cap Value ETF | 0.64297 | 53.47 | 0.25 |
| First Trust Value Line 100 ETF | 0.63 | 4.14 | 0.70 |
| iShares Morningstar Large-Cap ETF | 0.33152 | 184.21 | 0.03 |
| Columbia U.S. ESG Equity Income ETF | 0.29579 | -3.6 | 0.35 |
| JPMorgan Corporate Bond Research Enhanced ETF | 0.21 | 1.94 | 0.09 |
| 1.76 | 27.31 | 0.4 |
|---|
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Ms. Jennifer B. Damico | Senior VP, Controller & Principal Accounting Officer | N/A | 1968 (57 years) |
| Ms. Lidia L. Fonseca | Executive VP and Chief Digital & Technology Officer | N/A | 1969 (56 years) |
| Mr. Douglas M. Lankler | Executive VP & General Counsel | 1.76M | 1966 (59 years) |
| Dr. Mikael Dolsten M.D., Ph.D. | Chief Scientific Officer and President of Research & Development | 2.41M | 1958 (67 years) |
| Mr. David M. Denton | Chief Financial Officer & Executive VP | 1.75M | 1965 (60 years) |
| Mr. Rady A. Johnson | Executive VP and Chief Compliance, Quality & Risk Officer | N/A | 1962 (63 years) |
| Dr. Albert Bourla D.V.M., Ph.D. | Chairman of the Board & CEO | 4.05M | 1962 (63 years) |
| Ms. Francesca M. DeMartino | Chief Investor Relations Officer | N/A | |
| Mr. Andreas J. Panayiotou | Global Chief Marketing Officer | N/A | |
| Ms. Payal Sahni Becher | Chief People Experience Officer & Executive VP | 1975 (50 years) |
About company
Address: United States, New York, 235 East 42nd Street - Open in google maps, Open in yandex maps
Website: http://www.pfizer.com
Website: http://www.pfizer.com
